Physician profile
Matthew Melander
NPI 1174561211
$30,028.52
in general payments reported to CMS, 2019-2025
26 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $5,427 · 2021: $5,660 · 2022: $8,142 · 2023: $4,338 · 2024: $3,395 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,946 · Food and Beverage: $4,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,946.34 |
| Food and Beverage | $4,481.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $13,218.31 | 2019-2025 | Arthrex |
| Elite Orthopedics, LLC | $9,247.36 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $4,722.07 | 2019-2024 | Persona, Mymobility Platform, G7 Osseoti Acetabular Shell |
| Stryker Corporation | $1,535.27 | 2019-2025 | Mako, Triathlon, Insignia |
| Miach Orthopaedics, INC. | $280.40 | 2023 | |
| Medacta USA, INC. | $193.83 | 2020-2024 | |
| Depuy Synthes Sales INC. | $183.37 | 2019-2025 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $146.69 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $114.65 | 2019 | |
| Ibsa Pharma INC. | $57.86 | 2024-2025 | Licart, Tirosint, Flector |
| Ethicon US, LLC | $38.26 | 2022 | |
| Electronic Waveform Lab, INC. | $32.07 | 2019 | |
| Catalyst Orthoscience | $31.62 | 2022 | |
| Ferring Pharmaceuticals INC. | $29.66 | 2019-2020 | |
| Relievant Medsystems, INC. | $24.68 | 2023 | Intracept |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.09 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $21.39 | 2025 | Iovera, Zilretta |
| Kerecis Limited | $17.33 | 2022 | |
| Horizon Therapeutics Plc | $16.21 | 2019 | |
| Celularity INC. | $16.00 | 2019 | |
| Solventum Corporation | $14.46 | 2025 | Prevena |
| Organogenesis INC. | $14.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.23 | 2019 | |
| Baudax Bio INC. | $14.15 | 2020 | |
| Merck Sharp & Dohme LLC | $13.65 | 2022 | |
| Orthofix Medical, INC. | $8.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Melander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.